Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11007252 | 0.89 | FDPS (0.38) | FDPSCDK2LOXL2CCNE1CDK5 | |
| SCHEMBL11611429 | 0.88 | FDPS (0.40) | FDPSCDK2LOXL2CCNE1CDK5 | |
| SCHEMBL5888224 | 0.85 | FDPS (0.37) | FDPSCDK2LOXL2SLC5A2 | |
| SCHEMBL11613693 | 0.85 | LOXL2 (0.41) | FDPSLOXL2 | |
| SCHEMBL11612154 | 0.85 | FDPS (0.34) | FDPSLOXL2 | |
| SCHEMBL28216621 | 0.85 | LOXL2 (0.34) | FDPSLOXL2 | |
| SCHEMBL21725242 | 0.82 | FDPS (0.33) | FDPS | |
| SCHEMBL18758999 | 0.82 | FDPS (0.39) | FDPSCDK2 | |
| SCHEMBL11613295 | 0.82 | SLC5A2 (0.39) | FDPSCDK2CCNE1CDK5SLC5A2 | |
| SCHEMBL5888997 | 0.81 | CCNE1 (0.43) | FDPSCDK2CCNE1CDK5SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170336406-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | BIOINCEPT, LLC (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170336406-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | MIF, PGF, IRF2BP2 | FDPS 2029/4885CDK2 2766/4885LOXL2 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.